Literature DB >> 12008086

In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome.

Eugenia Flores-Figueroa1, Guillermo Gutiérrez-Espíndola, Juan José Montesinos, Rosa María Arana-Trejo, Hector Mayani.   

Abstract

In vitro studies on the functional integrity of the hematopoietic microenvironment in myelodysplasia have been controversial. Although some of them suggest that such a microenvironment is functionally normal, there is increasing evidence indicating that there are alterations in the function of microenvironment (adherent) cell layers from myelodysplastic syndromes (MDS) marrow. Adherent cell layers developed in vitro, however, consist of a mixture of different cell types-mostly fibroblasts and macrophages-thus, it is not clear which cell type(s) is(are) functionally abnormal in this disorder. In order to address this issue, in the present study, we first assessed some functional properties of MDS-derived adherent cell layers, as a whole, and then we analyzed those same functional properties after separating these cells into two different populations: a fibroblast-enriched cell layer and a macrophage-enriched cell layer. When whole adherent layers from MDS patients were analyzed, no significant differences were observed, as compared to their normal counterparts, in terms of morphology and total cell number. A major difference, however, was observed when analyzing the production of the cytokines interleukin-6 (IL-6) and tumor necrosis factor (TNF-alpha). Indeed, adherent layers from MDS patients produced higher levels of these cytokines (2- and 22-fold, respectively), as compared to normal layers. When fibroblast- and macrophage-enriched cell layers were analyzed, a higher apoptotic index was observed in those derived from MDS marrow (4% of TUNEL-positive cells in normal fibroblast layers versus 27% in MDS-derived fibroblast layers; 7% of TUNEL-positive cells in normal macrophage layers versus 24% in MDS macrophage layers). Macrophages from MDS marrow produced significantly higher levels of TNF-alpha (nine-fold) than their normal counterparts. MDS-derived fibroblasts, on the other hand, produced higher levels of IL-6 (nine-fold), as compared to normal fibroblasts. Surprisingly, whereas normal fibroblasts showed a discrete production of TNF-alpha, we found a very high production of this cytokine in cultures of fibroblasts from MDS patients. In summary, in the present study we have demonstrated that, at least in vitro, both fibroblasts and macrophages from MDS bone marrow (BM) are functionally abnormal. Such abnormalities include an increased apoptotic index, as well as a high production of both IL-6 and TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12008086     DOI: 10.1016/s0145-2126(01)00193-x

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  36 in total

1.  Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes.

Authors:  Carmen Mariana Aanei; Pascale Flandrin; Florin Zugun Eloae; Eugen Carasevici; Denis Guyotat; Eric Wattel; Lydia Campos
Journal:  Stem Cells Dev       Date:  2011-10-27       Impact factor: 3.272

2.  Adherence to macrophages in erythroblastic islands enhances erythroblast proliferation and increases erythrocyte production by a different mechanism than erythropoietin.

Authors:  Melissa M Rhodes; Prapaporn Kopsombut; Maurice C Bondurant; James O Price; Mark J Koury
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

Review 3.  Erythroblastic islands: niches for erythropoiesis.

Authors:  Joel Anne Chasis; Narla Mohandas
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

Review 4.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

5.  Myeloid malignancies and the microenvironment.

Authors:  Claudia Korn; Simón Méndez-Ferrer
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

6.  Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.

Authors:  Fernanda Marconi Roversi; Matheus Rodrigues Lopes; João Agostinho Machado-Neto; Ana Leda F Longhini; Adriana da Silva Santos Duarte; Mariana Ozello Baratti; Bruna Palodetto; Flávia Adolfo Corrocher; Fernando Vieira Pericole; Paula de Melo Campos; Patricia Favaro; Fabiola Traina; Sara Teresinha Olalla Saad
Journal:  Stem Cells Dev       Date:  2014-02-18       Impact factor: 3.272

7.  A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency.

Authors:  Carl R Walkley; Gemma Haines Olsen; Sebastian Dworkin; Stewart A Fabb; Jeremy Swann; Grant A McArthur; Susan V Westmoreland; Pierre Chambon; David T Scadden; Louise E Purton
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

Review 8.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

9.  Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.

Authors:  Gergely Varga; Judit Kiss; Judit Várkonyi; Virág Vas; Péter Farkas; Katalin Pálóczi; Ferenc Uher
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

10.  Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts.

Authors:  Mariana O Baratti; Yuri B Moreira; Fabiola Traina; Fernando F Costa; Sergio Verjovski-Almeida; Sara T Olalla-Saad
Journal:  BMC Med Genomics       Date:  2010-07-15       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.